BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
Status:
Active, not recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine safety signals and demonstrate seizure reduction in
adults with FIAS treated with BIS-001ER as an add-on therapy in an in-patient and out-patient
study design.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Biscayne Neurotherapeutics, Inc. Supernus Pharmaceuticals, Inc.